Pimavanserin:a New Drug for the Treatment of Psychosis Associated with Parkinson' s Disease
10.3969/j.issn.1008-049X.2017.09.032
- VernacularTitle:帕金森病相关精神症状治疗新药匹莫范色林
- Author:
Xianhong DONG
;
Jiang ZHU
;
Shuai MA
- Keywords:
Parkinson' s disease;
Psychosis;
Pimavanserin;
5-HT2A receptor inverse agonist
- From:
China Pharmacist
2017;20(9):1636-1638
- CountryChina
- Language:Chinese
-
Abstract:
Pimavanserin is a selective 5-HT2A receptor inverse agonist approved by FDA on April 29, 2016, and it is the first drug for the treatment of hallucinations and delusions associated with Parkinson' s disease. Pimavanserin is with high safety, good toleration and promising clinical efficiency, which is a timely option to resolve the drug shortage in clinic treatment. This paper summarized its pharmacodynamics, pharmacokinetics, clinical studies, adverse reactions and drug interactions.
